Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Obesity Surgery
Published in: Obesity Surgery 2/2014

01-02-2014 | Review Article

The Duodenal–Jejunal Bypass Liner for the Treatment of Type 2 Diabetes Mellitus and/or Obesity: a Systematic Review

Authors: Ingrid Zechmeister-Koss, Mirjana Huić, Stefan Fischer, for the European Network for Health Technology Assessment (EUnetHTA)

Published in: Obesity Surgery | Issue 2/2014

Login to get access

Abstract

This systematic literature review applies the GRADE approach to evaluate the efficacy and safety of the duodenal–jejunal bypass liner (DJBL) for the treatment of (a) patients with obesity ≥ grade II (with comorbidities) and (b) patients with type 2 diabetes mellitus + obesity ≥ grade I. We included ten studies with a total of 342 patients that primarily investigated a prototype of the DJBL. In high-grade obese patients, short-term excess weight loss was observed. For the remaining patient-relevant endpoints and patient populations, evidence was either not available or ambiguous. Complications (mostly minor) occurred in 64–100 % of DJBL patients compared to 0–27 % in the control groups. Gastrointestinal bleeding was observed in 4 % of patients. We do not yet recommend the device for routine use.
Literature
1.
2.
3.
Elmadfa I, Hasenegger V, Wagner K, et al. Österreichischer Ernährungsbericht 2012. Vienna: Institut für Ernährungswissenschaften; 2012.
4.
5.
National Institute for Health and Clinical Excellence. Obesity: guidance on the prevention, identification, assessment and management of overweight and obesity in adults and children. London: National Institute for Health and Clinical Excellence; 2006.
6.
Scottish Intercollegiate Guidelines Network. Management of obesity: a national clinical guideline. Edinburgh: Scottish Intercollegiate Guidelines Network; 2010.
7.
American Diabetes Association. Standards of medical care in diabetes. Diabetes Care. 2013;36:S11–66.CrossRef
8.
Scottish Intercollegiate Guidelines Network. Management of diabetes. Edinburgh: Scottish Intercollegiate Guidelines Network; 2010.
9.
The Royal College of Physicians. Type 2 diabetes. National clinical guideline for primary and secondary care (update). London: The Royal College of Physicians; 2008.
10.
ECRI Institute. AHRQ health care horizon scanning system—potential high-impact interventions report. Priority area 10: obesity. (Prepared by ECRI Institute under Contract No. HHSA290201000006C.). Rockville: Agency for Healthcare Research and Quality; 2012.
11.
National Institute for Health and Clinical Excellence. Bariatric surgical service for the treatment of people with severe obesity. Commissioning guide. London: National Institute for Health and Clinical Excellence; 2007.
12.
National Institute for Health and Clinical Excellence. Interventional procedure overview of implantation of a duodenal–jejunal bypass sleeve for managing obesity. London: National Institute for Health and Clinical Excellence; 2012.
13.
Australian Government: Department of Health and Ageing. Horizon scanning technology prioritising summary. In: EndoBarrier Gastrointestinal Liner for obesity. Series horizon scanning technology prioritising summary. Commonwealth of Australia; 2010. p. 10.
14.
Gartlehner G. Internes manual. Abläufe und Methoden. Teil 2 (2nd Ed.). LBI-HTA Projektbericht 006 2008; (6):1–79.
15.
European Network for Health Technology Assessment (EUnetHTA). Endpoints used for relative effectiveness assessment of pharmaceuticals: clinical endpoints. Copenhagen: EUnetHTA; 2013.
16.
17.
18.
Atkins D, Eccles M, Flottorp S, et al. Systems for grading the quality of evidence and the strength of recommendations I: critical appraisal of existing approaches. The GRADE Working Group. BMC Health Serv Res. 2004;4(1):38.PubMedCentralPubMedCrossRef
19.
Gersin KS, Rothstein RI, Rosenthal RJ, et al. Open-label, sham-controlled trial of an endoscopic duodenojejunal bypass liner for preoperative weight loss in bariatric surgery candidates. Gastrointest Endosc. 2010;71(6):976–82.PubMedCrossRef
20.
Rodriguez L, Reyes E, Fagalde P, et al. Pilot clinical study of an endoscopic, removable duodenal-jejunal bypass liner for the treatment of type 2 diabetes. Diabetes Technol Ther. 2009;11(11):725–32.PubMedCrossRef
21.
Schouten R, Rijs CS, Bouvy ND, et al. A multicenter, randomized efficacy study of the EndoBarrier gastrointestinal liner for presurgical weight loss prior to bariatric surgery. Ann Surg. 2010;251(2):236–43.PubMedCrossRef
22.
Tarnoff M, Rodriguez L, Escalona A, et al. Open label, prospective, randomized controlled trial of an endoscopic duodenal–jejunal bypass sleeve versus low calorie diet for pre-operative weight loss in bariatric surgery. Surg Endosc. 2009;23(3):650–6.PubMedCrossRef
23.
Cohen RV, Galvao Neto MP, Correa J, et al. A pilot study of the duodenal–jejunal bypass liner in low body mass index type 2 diabetes. J Clin Endocrinol Metab. 2013;98(2):E279–82.PubMedCrossRef
24.
de Moura EGH, Orso IRB, Martins BC, et al. Improvement of insulin resistance and reduction of cardiovascular risk among obese patients with type 2 diabetes with the duodenojejunal bypass liner. Obes Surg. 2011;21(7):941–7.PubMedCrossRef
25.
de Moura EGH, Martins BC, Lopes GS, et al. Metabolic improvements in obese type 2 diabetes subjects implanted for 1 year with an endoscopically deployed duodenal–jejunal bypass liner. Diabetes Technol Ther. 2012;14(2):183–9.PubMedCrossRef
26.
Escalona A, Yanez R, Pimentel F, et al. Initial human experience with restrictive duodenal–jejunal bypass liner for treatment of morbid obesity. Surg Obes Relat Dis. 2010;6(2):126–31.PubMedCrossRef
27.
Escalona A, Pimentel F, Sharp A, et al. Weight loss and metabolic improvement in morbidly obese subjects implanted for 1 year with an endoscopic duodenal–jejunal bypass liner. Ann Surg. 2012;255(6):1080–5.PubMedCrossRef
28.
Rodriguez-Grunert L, Galvao Neto MP, Alamo M, et al. First human experience with endoscopically delivered and retrieved duodenal–jejunal bypass sleeve. Surg Obes Relat Dis. 2008;4(1):55–9.PubMedCrossRef
29.
Patel SR, Hakim D, Mason J, et al. The duodenal–jejunal bypass sleeve (EndoBarrier Gastrointestinal Liner) for weight loss and treatment of type 2 diabetes. Surg Obes Relat Dis 2013;9:482–4.
Metadata
Title
The Duodenal–Jejunal Bypass Liner for the Treatment of Type 2 Diabetes Mellitus and/or Obesity: a Systematic Review
Authors
Ingrid Zechmeister-Koss
Mirjana Huić
Stefan Fischer
for the European Network for Health Technology Assessment (EUnetHTA)
Publication date
01-02-2014
Publisher
Springer US
Published in
Obesity Surgery / Issue 2/2014
Print ISSN: 0960-8923
Electronic ISSN: 1708-0428
DOI
https://doi.org/10.1007/s11695-013-1137-2

Other articles of this Issue 2/2014

Obesity Surgery 2/2014 Go to the issue

Original Contributions

Aprepitant’s Prophylactic Efficacy in Decreasing Postoperative Nausea and Vomiting in Morbidly Obese Patients Undergoing Bariatric Surgery

Original Contributions

Long-Term Results of a Prospective Comparison of Roux-en-Y Gastric Bypass versus a Variant of Biliopancreatic Diversion in a Non-Superobese Population (BMI 35–50 kg/m2)

Review Article

Controversy Surrounding ‘Mini’ Gastric Bypass

Original Contributions

Excess Body Weight Loss is Associated with Nonpathological Gait Patterns in Women 4 to 5 Years After Bariatric Surgery

Original Contributions

Prophylaxis of Venous Thromboembolism with Low Molecular Weight Heparin in Bariatric Surgery: a Prospective, Randomised Pilot Study Evaluating Two Doses of Parnaparin (BAFLUX Study)

Review Article

Development of Ulcer Disease After Roux-en-Y Gastric Bypass, Incidence, Risk Factors, and Patient Presentation: A Systematic Review